This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Enhanc3D Genomics

Profile

Enhanc3D Genomics has established a genome-wide 3D-sequencing platform (GenLink3DTM) using proprietary technology that can globally connect enhancer regions and GWAS (genome-wide association study) risk loci to their core target genes. The human genome is highly organised and compact in the nucleus, resulting in long-range promoter-enhancer interactions. This 3D DNA folding underpins genome function – by bringing thousands of non-coding enhancer regions into proximity with coding genes. The 3D organisation of the genome therefore represents a fundamental and untapped layer of genome regulation. 3D genomics demonstrates this long-range gene regulation and is a critical part of a comprehensive “omics” analysis to understand disease mechanisms Only 2% of DNA codes for proteins, whilst the non-coding genome (98%) harbours the vast majority of regulatory elements that control the expression of these protein-coding genes. 95% of disease-associated genetic loci, identified by genome-wide association studies (GWAS), reside in non-coding DNA – the majority of which have enhancer features – making them difficult to interpret and target therapeutically. Aligned with a machine learning platform and a unique business model, Enhanc3D Genomics is mining this untapped resource of non-coding genome interactions to create an extensive database of candidate therapeutic targets for development with pharmaceutical partners. Enhan3D Genomics is applying this technology into multiple therapeutic areas, including immunology, immune-oncology and ageing, and is now actively seeking pharma partners and additional growth investors to further translate its unique “big-data” position in the field of functional genomics.